Catalog No.
Product Name
Application
Product Information
Citations
-
BChE Inhibitor
BChE-IN-6 is a potent butyrylcholinesterase (BChE) inhibitor, exhibiting a Ki of 0.182 μM. This compound possesses chelating properties for Zn2+, making it a valuable tool for studying metal interactions in biological systems. BChE-IN-6 is primarily utilized in Alzheimer's disease research, aiding in the investigation of cholinergic dysfunction and potential therapeutic interventions. -
Acetylcholinesterase Inhibitor
Pirimiphos ethyl is an organophosphorus compound that functions as an acetylcholinesterase inhibitor. Its primary biological activity involves disrupting the normal hydrolysis of acetylcholine, resulting in prolonged neurotransmission at cholinergic synapses. This reagent is utilized extensively in agricultural research to study the effects of pesticide exposure on neurological pathways and to assess the ecological impact of pesticide application. -
AChE-MAO B Inhibitor
Dual AChE-MAO B-IN-2 is a powerful inhibitor of both acetylcholinesterase (AChE) and monoamine oxidase B (MAO B), exhibiting IC50 values of 0.12 µM and 0.01 µM, respectively. This dual inhibition profile suggests its significant potential in the study and development of therapeutic strategies for Alzheimer's disease. Researchers can utilize Dual AChE-MAO B-IN-2 to explore mechanisms related to cholinergic dysfunction and oxidative stress in neurodegenerative conditions. -
AchE Inhibitor
Pumiloside is a natural compound isolated from Nauclea officinalis that functions as an acetylcholinesterase (AChE) inhibitor, demonstrating an IC50 value of 118.36 μM. This compound is of significant interest for research applications related to neurodegenerative disorders, where modulation of cholinergic signaling may be beneficial. Pumiloside's ability to inhibit AChE positions it as a potential candidate for the development of therapeutic agents targeting cognitive decline. -
hBChE Inhibitor
Echothiopate iodide is a potent inhibitor of human butyrylcholinesterase (hBChE), known for its ability to prolong cholinergic activity. As a long-acting anticholinesterase agent, this compound is particularly relevant in studies related to glaucoma and acetylcholine signaling pathways. Its inhibitory effects make it a valuable tool for investigating cholinergic modulation and potential therapeutic interventions in related disorders. -
AChE Inhibitor
AChE-IN-7 is a highly selective and potent inhibitor of acetylcholinesterase with an eeAChE IC50 value of 0.045 μM and an eeBuChE IC50 of 19.68 μM. This compound demonstrates promising in vivo and in vitro safety profiles, along with favorable pharmacokinetic characteristics and high bioavailability (F = 55.5%). Additionally, AChE-IN-7 exhibits significant permeability across the blood-brain barrier, making it a valuable tool for research into neurological disorders and therapeutic strategies targeting cholinergic signaling. -
AChE Inhibitor
AChE-IN-44 is a potent acetylcholinesterase (AChE) inhibitor. It effectively enhances cholinergic neurotransmission by inhibiting the breakdown of acetylcholine, making it valuable for research in neurodegenerative diseases such as Alzheimer's. Additionally, AChE-IN-44 can be transformed into the thiazole salt derivative, AChE inhibitor Tat2, expanding its potential applications in pharmacological studies. -
Stable Isotope
Profenofos-d3 is a stable isotope-labeled derivative of Profenofos, an insecticide known for its application in field crops, vegetables, and fruit crops. It functions as an acetylcholinesterase (AChE) inhibitor, exhibiting neurotoxic effects that can impact insect populations. This reagent is valuable for research applications involving pharmacokinetics and metabolic studies of insecticides, enabling precise tracking in biological systems. -
BuChE Inhibitor
BuChE-IN-3 is a selective inhibitor of butyrylcholinesterase (BuChE) with an IC50 of 8.3 nM. This compound demonstrates neuroprotective properties and exhibits mild antioxidant activity, making it suitable for studies related to neurodegenerative diseases. Its favorable lipophilicity and low toxicity profile further support its potential in chemical research applications aimed at exploring BuChE's role in various biological processes. -
AChE Reactivator
K203 is a potent reactivator of acetylcholinesterase (AChE) inhibited by tabun. This compound is a vital antidote for organophosphate poisoning, restoring AChE activity and mitigating the toxic effects of nerve agents. Its application is significant in toxicology research and therapeutic interventions for chemical warfare agent exposure. -
Cholinesterase (ChE) Inhibitor
Echimidine N-oxide is a pyrrolizidine alkaloid that serves as an acetylcholinesterase (AChE) inhibitor, exhibiting an IC50 value of 0.347 mM. This compound is utilized in research applications focusing on neurological disorders and cholinergic system modulation. Its inhibitory activity on ChE provides valuable insights into potential therapeutic strategies for conditions associated with cholinergic dysregulation. -
ChEs/MAOs Inhibitor
ChEs/MAOs-IN-2 is a potent inhibitor of cholinesterases and monoamine oxidases, exhibiting IC50 values of 0.10 µM for MAO-A, 0.20 µM for MAO-B, 0.30 µM for acetylcholinesterase (AChE), and 0.40 µM for butyrylcholinesterase (BChE). This compound demonstrates significant biological activity relevant to neurodegenerative diseases, particularly Alzheimer's disease, and serves as a valuable tool for research into therapeutic strategies targeting these enzymes. -
AChE Inhibotor
Huperzine C is an alkaloid derived from Huperzia serrate, functioning as a potent acetylcholinesterase (AChE) inhibitor with an IC50 value of 0.6 μM. This compound has demonstrated significant biological activity in enhancing acetylcholine levels, making it a valuable tool for research related to Alzheimer’s disease and other neurodegenerative disorders. Its mechanism of action highlights its potential utility in studies aimed at developing therapeutic strategies for cognitive decline. -
AChE Inhibitor
Scutellarein 4'-methyl ether 7-O-glucuronide is a flavonoid compound that acts as an inhibitor of acetylcholinesterase (AChE), with an IC50 value of 1 mg/mL. Isolated from Plectranthus barbatus, this compound exhibits antioxidant properties and is significant for research into neurological disorders, particularly Alzheimer's disease. Its dual function as an AChE inhibitor and antioxidant makes it valuable for studies exploring therapeutic strategies in cognitive health. -
AChE Inhibitor
Rivastigmine metabolite (NAP 226-90) is an acetylcholinesterase (AChE) inhibitor that plays a significant role in the modulation of cholinergic neurotransmission. This compound is a key metabolite formed in the kidney and is of particular interest for research into Alzheimer's Disease. Its inhibitory action on AChE highlights its potential for studying therapeutic approaches in neurodegenerative conditions characterized by cholinergic deficits. -
Acetylcholinesterase Inhibitor
Protopine hydrochloride is a reversible and competitive inhibitor of acetylcholinesterase. This isoquinoline alkaloid demonstrates significant anti-inflammatory, antimicrobial, anti-angiogenic, and anti-tumor properties. It can be utilized in various research applications, particularly in studies related to neurodegenerative diseases, cancer, and inflammatory disorders. -
AChE Inhibitor
Stemoninine is a lycoris alkaloid that acts as an inhibitor of acetylcholinesterase (AChE), exhibiting a significant inhibitory effect with an IC50 value of 5.52 μM. This compound demonstrates potential antitussive properties, making it a valuable reagent for research involving respiratory conditions and cholinergic signaling pathways. Its ability to modulate AChE activity is important for studies focusing on neurodegenerative diseases and synaptic transmission. -
ChE Inhibitor
Hexafluorenium dibromide is a potent cholinesterase (ChE) inhibitor, exhibiting a pI50 value of 6.96 and a Ki value of 2.4 nM for human plasma cholinesterase. This compound is primarily utilized in research focused on the modulation of cholinergic activity and is relevant for studies investigating neurodegenerative diseases and muscle disorders. Its strong inhibition of ChE makes it a valuable tool for exploring the dynamics of acetylcholine in biological systems. -
AChE/BChE Inhibitor
Octahydroaminoacridine is a potent inhibitor of acetylcholinesterase (AChE) and butyrylcholinesterase (BChE), serving as a valuable tool in cholinergic research. Its activity can enhance understanding of neurodegenerative conditions, particularly Alzheimer's disease (AD). This compound offers insight into mechanisms of cholinesterase inhibition, supporting the development of therapeutic strategies for cognitive disorders. -
Acetylcholinesterase Inhibitor
(E)-2-Nitrocinnamic acid is an effective acetylcholinesterase inhibitor. Its primary mechanism of action involves the modulation of acetylcholine levels, which is significant for neurochemical research. This compound is particularly relevant for studies related to Alzheimer's disease and other neurodegenerative disorders, providing valuable insights into potential therapeutic approaches. -
AChE Inhibitor
DCDQ is a potent inhibitor of acetylcholinesterase (AChE), demonstrating strong binding affinity for the 4EY7 protein with a binding energy of −8.2 kcal/mol. This compound is of significant interest in the research of Alzheimer's disease (AD), where AChE inhibition may enhance cholinergic transmission and potentially improve cognitive function. DCDQ serves as a valuable tool for investigating therapeutic strategies aimed at mitigating the effects of neurodegenerative disorders. -
AchE Inhibitor
Territrem C is a potent acetylcholinesterase (AChE) inhibitor, exhibiting an IC50 value of 0.23 μM. This compound, categorized as an α-pyrone meroterpenoid, is derived from the fungus Penicillium sp. SK5GW1L. Territrem C is primarily utilized in biological research to study cholinergic signaling pathways and to explore potential therapeutic strategies for conditions associated with AChE dysfunction. -
AChE/BChE Inhibitor
AChE/BChE-IN-8 is an uncompetitive inhibitor of acetylcholinesterase (AChE) and a mixed inhibitor of butyrylcholinesterase (BChE), demonstrating Ki values of 0.788 μM and 2.364 μM against Electrophorus electricus AChE and equine BChE, respectively. This compound is capable of crossing the blood-brain barrier and exhibits low cytotoxicity, making it suitable for neurological research applications. AChE/BChE-IN-8 can be effectively utilized in studies focused on cholinergic signaling, neurodegenerative diseases, and the modulation of cholinergic activity. -
Cholinesterase Inhibitor
RX 67668 is a potent cholinesterase inhibitor, demonstrating an IC50 of 5 μM for both acetylcholinesterase (AChE) and butyrylcholinesterase. This compound effectively reverses neuromuscular blockade induced by D-tubocurarine. RX 67668 has applications as a muscle relaxant and is utilized in research focused on alleviating skeletal muscle fatigue. -
Acetylcholinesterase Inhibitor
Dehydrogeijerin is a potent inhibitor of acetylcholinesterase, exhibiting an IC50 value of 9.7 μM. This compound is particularly relevant for research into Alzheimer’s disease, where the modulation of acetylcholine levels can influence disease pathology. Dehydrogeijerin's ability to inhibit acetylcholinesterase makes it a valuable tool for exploring therapeutic strategies aimed at enhancing cholinergic signaling in neurodegenerative disorders. -
AChE Inhibitor
AChE-IN-86 is a potent inhibitor of acetylcholinesterase (AChE), exhibiting an IC50 of 25.33 μg/mL. This compound effectively inhibits AChE by forming hydrogen bonds and π-π and π-alkyl interactions with critical amino acid residues at the enzyme's catalytic sites. AChE-IN-86 is applicable in research focused on Alzheimer's disease, making it a valuable tool for studying cholinergic dysfunction associated with neurodegeneration. -
Acetylcholinesterase Inhibitor
Paecilomide is a pyridone alkaloid that acts as an acetylcholinesterase inhibitor. This compound exhibits key biological activity by enhancing cholinergic signaling, making it significant for research applications related to neurodegenerative diseases such as Alzheimer's. Its ability to inhibit acetylcholinesterase enables the study of cholinergic neurotransmission and potential therapeutic interventions. -
AChE Inhibitor
AChE-IN-25 is a potent and selective uncompetitive inhibitor of acetylcholinesterase (AChE), exhibiting an IC50 value of 2.95 µM. This compound demonstrates significant potential for modulating cholinergic activity, making it a valuable tool in Alzheimer's disease research and related neurodegenerative studies. Its ability to effectively inhibit AChE can aid in understanding and investigating therapeutic strategies targeting cholinergic deficiencies. -
Acetylcholinesterase inhibitor
AChE-IN-37 is an acetylcholinesterase inhibitor featuring an IC50 value of 0.23 μM. This compound modulates reactive oxygen species (ROS) levels and influences the gene expression of NRF2. AChE-IN-37 is applicable in research focused on neurodegenerative diseases and oxidative stress-related studies. -
BChE Inhibitor
Z164597606 is a selective butyrylcholinesterase (BChE) inhibitor, demonstrating IC50 values of 1.3 μM and 1.7 μM for equine and human BChE, respectively. The compound interacts with the enzyme through π-π stacking with the Trp82 residue, facilitating its inhibitory effect. Z164597606 is applicable in research focused on Alzheimer’s disease, enabling investigations into therapeutic strategies targeting cholinesterase activity. -
Cholinesterase (ChE)
Anisopirol (R-2159) functions as an inhibitor of cholinesterase (ChE), which is crucial for neurotransmitter regulation. Research indicates that it may exhibit neuroprotective effects and could modulate various protein targets implicated in Alzheimer's disease. This compound is primarily utilized in studies focused on understanding the biochemical pathways involved in neurodegeneration and potential therapeutic strategies for Alzheimer's disease. -
AChE Inhibitor
AChE-IN-91 is a potent acetylcholinesterase (AChE) inhibitor with an IC50 of 0.05 μM. It exhibits significant anticholinesterase activity, making it a valuable tool for research into neurological disorders, particularly Alzheimer's disease. This compound facilitates the study of cholinergic signaling and potential therapeutic strategies in neurodegeneration. -
AChE Inhibitor
Isocorydine N-oxide is an alkaloid that functions as an acetylcholinesterase (AChE) inhibitor. This compound exhibits significant activity that may contribute to the modulation of neurotransmitter levels, making it a valuable tool in research focused on neurodegenerative diseases such as Alzheimer's disease. It is utilized to explore therapeutic strategies aimed at enhancing cholinergic function and improving cognitive outcomes in affected individuals. -
Xanthohumol Derivative
Xanthohumol I is a chalcone derivative of Xanthohumol, known for its role as a Cholinesterase (ChE) inhibitor. It effectively inhibits acetylcholinesterase (AChE) and butyrylcholinesterase (BChE) with IC50 values of 71.34 μM and 32.67 μM, respectively. Additionally, its hydroxy derivative, 3-hydroxy-xanthohumol, also demonstrates inhibitory effects on AChE and BChE, with IC50 values of 51.25 μM and 63.07 μM. This compound is valuable for research in neurodegenerative diseases and related biochemical pathways. -
BChE Inhibitor
BChE-IN-20 is a potent and selective inhibitor of butyrylcholinesterase (BChE), demonstrating IC50 values of 105 nM for equine BChE and 2.3 nM for human BChE. Additionally, it inhibits P-glycoprotein with an IC50 of 0.27 μM. This compound serves as a valuable template for the design and development of BChE-selective ligands relevant to pharmacological research, including inhibitors and fluorogenic probes. -
BChE Inhibitor
Blestrin D is a potent mixed-type inhibitor of butyrylcholinesterase (BChE), exhibiting an IC50 value of 8.1 μM. Isolated from Bletilla striata, this compound is valuable for investigating the biochemical pathways involved in Alzheimer's disease (AD). Its ability to inhibit BChE makes it an important tool for studying cholinergic dysfunction associated with neurodegenerative conditions. -
AChE Inhibitor
AChE-IN-22 is a selective inhibitor of acetylcholinesterase (AChE) and butyrylcholinesterase (BuChE), exhibiting IC50 values of 0.88 μM and 10 μM, respectively. This compound interacts with both the catalytic active site (CAS) and peripheral anionic site (PAS) of AChE, making it a valuable tool for studies related to Alzheimer's disease. AChE-IN-22 is suitable for research applications focused on cholinergic system modulation and neurodegenerative disease mechanisms. -
Cholinesterase (ChE) Inhibitor
eeAChE-IN-2 is a highly potent inhibitor of acetylcholinesterase (AChE), exhibiting an IC50 value of 2 nM. This compound serves as a valuable tool for studying cholinergic signaling and its modulation in various biological systems. Its application extends to research on neurodegenerative disorders and cognitive function, where AChE inhibition plays a critical role. -
AChE/BChE Inhibitor
AChE/BChE-IN-5 is a dual inhibitor of acetylcholinesterase (AChE) and butyrylcholinesterase (BChE) with IC50 values of 266 nM and 10.6 nM against human AChE (hAChE) and human BChE (hBChE), respectively. This compound is capable of crossing the blood-brain barrier (BBB), making it significant for research in neurodegenerative diseases and cognitive disorders. It serves as a valuable tool for studying the modulation of cholinergic signaling and the potential therapeutic effects in conditions such as Alzheimer's disease. -
AChE Inhibitor
Isonaringin is an acetylcholinesterase (AChE) inhibitor that demonstrates potential anti-Alzheimer's activity. By inhibiting AChE, Isonaringin increases acetylcholine levels in the brain, which may help improve cognitive function in neurodegenerative conditions. This compound is relevant for research applications focused on Alzheimer's disease and other related disorders. -
AChE Inhibitor
Zifrosilone is an orally active acetylcholinesterase (AChE) inhibitor, exhibiting a mean maximum inhibition of 20.9% at a dosage of 10 mg. This compound is useful in the study of neurological disorders, providing a valuable tool for research into conditions related to cholinergic dysfunction. Its selective targeting of AChE makes it an important reagent for investigating therapeutic strategies in neurodegenerative diseases. -
AChE Inhibitor
Ambenonium dichloride tetrahydrate is a potent, orally active, reversible inhibitor of acetylcholinesterase (AChE). This compound demonstrates a high affinity for human AChE, with an IC50 value of 0.7 nM, making it valuable for investigations into cholinergic system modulation. Its primary applications include the study of neurodegenerative diseases such as myasthenia gravis and Alzheimer's disease, as well as broader neuropharmacological research. -
BuChE Inhibitor
BuChE-IN-1 is a potent inhibitor of butyrylcholinesterase (BuChE), a key enzyme implicated as a biomarker in the progression of Alzheimer’s disease (AD). This compound exhibits low cytotoxicity and demonstrates excellent permeability across the blood-brain barrier (BBB). BuChE-IN-1 is an advantageous tool for investigating the role of BuChE in AD research and exploring therapeutic interventions. -
AChE Inhibitor
K027 is a potent reactivator of acetylcholinesterase (AChE) inhibited by organophosphates (OP). It effectively restores AChE activity, making it valuable for studying neurodegenerative conditions such as Alzheimer's disease. K027's mechanism and specificity provide a useful tool for investigating therapeutic strategies targeting cholinergic dysfunction. -
Cholinesterase (ChE) Inhibitor
hAChE-IN-4 is a potent inhibitor of human acetylcholinesterase (hAChE) with an IC50 value of 0.25 μM, demonstrating effective permeability across the blood-brain barrier. This compound plays a significant role in research related to Alzheimer's disease, where modulation of cholinergic activity is critical. Its use can aid in exploring therapeutic strategies targeting cholinesterase activity in neurodegenerative disorders. -
AChE Inhibitor
AChE-IN-26 is an acetylcholinesterase (AChE) inhibitor with a reported IC50 of 0.42 μM. This compound plays a significant role in research related to Alzheimer's disease by inhibiting the breakdown of acetylcholine, thereby enhancing cholinergic transmission. AChE-IN-26 serves as a valuable tool for studying pathophysiological mechanisms associated with neurodegeneration and for evaluating potential therapeutic strategies. -
Cholinesterase Inhibitor
Magnotriol B is a potent cholinesterase inhibitor, demonstrating IC50 values of 12.63 nM against acetylcholinesterase (AChE) and 14.5 nM against butyrylcholinesterase (BChE). Additionally, it exhibits notable nitric oxide (NO) inhibitory activity, with an IC50 of 2.02 μM. This compound is applicable in research focused on neurodegenerative disorders and inflammatory diseases, offering potential insights into therapeutic strategies targeting cholinergic dysfunction. -
AChE Inhibitor
Chikusetsusaponin Ib is a potent inhibitor of acetylcholinesterase (AChE), a key enzyme involved in neurotransmission. This compound exhibits significant anti-Alzheimer's disease activity, making it a valuable tool for research focused on neurodegenerative disorders. Its ability to modulate AChE activity can aid in the exploration of therapeutic strategies aimed at enhancing cognitive function and addressing Alzheimer’s pathology. -
AChE Inhibitor
Picfeltarraegenin X is a triterpenoid that functions as an acetylcholinesterase (AChE) inhibitor. This compound exhibits notable biological activity by enhancing acetylcholine levels, making it relevant for studies focused on neurodegenerative disorders such as Alzheimer's disease. Picfeltarraegenin X is useful in research applications aimed at understanding cholinergic signaling and developing potential therapeutic strategies targeting cognitive decline. -
Cholinesterase (ChE)
(Rac)-TZ3O primarily targets cholinesterase (ChE) and acts as an anticholinergic compound with neuroprotective properties. This compound has demonstrated the ability to ameliorate memory impairment and cognitive decline in rat models of Alzheimer's disease induced by scopolamine. (Rac)-TZ3O is valuable for research into neurodegenerative conditions, particularly in studying the mechanisms underlying Alzheimer's disease and potential therapeutic interventions.
